Frontiers | Clinical practice guidelines for acute kidney injury: a systematic review of the methodological quality ObjectiveHospitalized patients, particularly those in the ICU, face a significant risk of acute kidney injury (AKI). Clinical practice guidelines (CPGs) that...

📚 A 2025 review confirms KDIGO 2012 as the leading AKI guideline (doi.org/10.3389/fmed.2025.1567359).

Arch Biopartners’ Phase II trial for CS‑AKI uses KDIGO to define AKI after cardiac surgery.

🔬 archbiopartners.com/our-science/metablok

#AKI #CSAKI #NephSky #ArchScience #LSALTpeptide

Frontiers | Immune checkpoint inhibitors and acute kidney injury As a new type of anti-tumor immunotherapy, immune checkpoint inhibitors (ICIs) have improved the prognosis of multiple malignancies. However, renal complicat...

A 2024 Frontiers review (doi.org/10.3389/fimmu.2024.1353339) shows how cancer immunotherapies can trigger acute kidney injury (AKI).

Part of a 2025 research topic highlighting AKI and the urgent need for kidney protection.

🔬 archbiopartners.com/our-science

#AKI #KidneyCare #ArchScience #NephSky

Peritoneal dialysis in acute kidney injury: twenty years of experience at a single center in a developing country - Journal of Nephrology Background This study aimed to explore the role of peritoneal dialysis (PD) in patients with acute kidney injury (AKI) in relation to metabolic and fluid control, outcome and risk factors for death. M...

🔬A 20-year study in the Journal of Nephrology highlights the burden of AKI in critical care.

Arch is supporting two Phase II trials targeting CS-AKI and DI-AKI. Arch’s clinical programs (archbiopartners.com/our-science)

#AKI #TrialRationale #ArchScience

Full – doi.org/10.1007/s40620-024-02189-y

Acute Kidney Injury Is Associated With Increased Long-Term Mortality After Cardiothoracic Surgery | Circulation Background— Long-term survival after acute kidney injury (AKI) is poorly studied. We report the relationship between long-term mortality and AKI with small changes in serum creatinine during hospitali...

Friday Deep Dive — 2009 study in “Circulation” (doi.org/10.1161/CIRCULATIONAHA.108.800011) found cardiac surgery–associated AKI predicts higher long-term mortality, even years after discharge.
🔬 International CS-AKI Phase II Trial: archbiopartners.com/our-science
#CSAKI #KidneyCare #ArchScience

Our Science – Arch Biopartners

💰 2022 study in J Crit Care (doi.org/10.1016/j.jcrc.2021.12.011) found delayed RRT in CS-AKI = longer ICU stays and higher costs.

Arch’s science program is focused on preventing CS-AKI and improving patient outcomes.

🔬 archbiopartners.com/our-science/

#CSAKI #ArchScience #AKI #KidneyCare

Cardiac Surgery–Associated Acute Kidney Injury : Kidney360 [CSA-AKI]) on the basis of changes in serum creatinine and/or urine output. There are various preoperative, intraoperative, and postoperative risk factors for the development of CSA-AKI which should b...

📚 2024 review in Kidney360 (doi.org/10.34067/KID.0000000000000466) emphasizes the burden of CS-AKI, with inflammation and ischemia as central causes—and no approved treatments available.

🔬 Arch is focused on prevention: archbiopartners.com/our-science/

#CSAKI #AKI #KidneyCare #ArchScience

Our Science – Arch Biopartners

🌐 Cardiac surgery demand exceeds global capacity 12-to-1 (June 2024 - doi.org/10.1016/j.atssr.2023.11.019).

As access grows, so does the burden of CS-AKI—and the need for prevention.

📖 Learn more: archbiopartners.com/our-science

#ArchBiopartners #CSAKI #TrialRationale #ArchScience #InvestorFAQ

Trends in Hospitalizations for Acute Kidney Injury --- United ... Acute kidney injury is a sudden decrease in kidney function with or without kidney damage, occurring over a few hours or days.

📈 A CDC-backed study in MMWR (doi.org/10.15585/mmwr.mm6710a2) found AKI-related hospitalizations in the U.S. increased 4x from 2000 to 2014.
This sharp rise highlights AKI as an urgent unmet need in clinical care.
🔬 Phase II AKI trials - archbiopartners.com/our-science/
#AKI #KidneyCare #ArchScience

Practice Variation in Cardiac Surgery and Acute Kidney Injury This cohort study assesses operating room practices for vasopressor infusions, inotrope infusions, red blood cell transfusions, and fluid volume administration and their association with postsurgical ...

🩺 A 2025 JAMA Network Open study (doi.org/10.1001/jamanetworkopen.2025.8342) finds CS-AKI rates vary widely—11.7% to 32.8%—driven by intraoperative practices.

🔔 How Arch is addressing AKI in cardiac surgery: archbiopartners.com/our-science

#CSAKI #AKI #ArchScience #TrialRationale #KidneyCare

Redirecting

🧬 Weekly series for new followers—2019 Cell paper (doi.org/10.1016/j.cell.2019.07.017), co-authored by Arch scientists, identified DPEP1 as a driver of neutrophil inflammation in the kidneys, liver, and lungs.
📖 Arch Publications: dub.sh/cell-dpep1-2019
#DPEP1 #ArchScience #LSALTpeptide #KidneyCare

🩺 A 2025 review (doi.org/10.36348/sjmps.2025.v11i03.009 - PDF) finds ICU trauma patients are at high risk for AKI due to rhabdomyolysis, obesity, and hemodynamic stress.

🔔 More about Arch's work to prevent AKI: archbiopartners.com/our-science

#ArchBiopartners #AKI #ArchScience #TrialRationale

Cilastatin – Arch Biopartners

As part of a new series revisiting key research, Arch is highlighting a 2018 JCI study (doi.org/10.1172/JCI96640) showing how Cilastatin blocks DPEP1-driven contrast uptake and protects kidney function in AKI models.
📖 archbiopartners.com/our-science/cilastatin/
#Cilastatin #DPEP1 #ArchScience

Our Science – Arch Biopartners

Arch Biopartners is advancing two lead drug candidates:

🧪 LSALT peptide: targets inflammation-related AKI
🔬 Cilastatin: repurposed to prevent toxin-related AKI

Learn more: archbiopartners.com/our-science

#ArchBiopartners #AKI #LSALTpeptide #Cilastatin #ArchScience